Form 4: Cidara Therapeutics Director Ryan Spencer Acquires Stock Options

Director Ryan Spencer acquired 4,250 stock options in Cidara Therapeutics on April 26, 2024, at an exercise price of $12.63.

Summary

• On April 26, 2024, Ryan Spencer, a director of Cidara Therapeutics, acquired 4,250 stock options.
• The exercise price for these options is $12.63.
• The options vest over a period of three years, with one-third vesting on April 26, 2025, and the remaining two-thirds vesting in equal monthly installments until April 26, 2027.
• The options expire on April 25, 2034.
• Following the transaction, Spencer directly owns 4,250 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants to a director, which doesn't inherently indicate positive or negative sentiment.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders (such as directors or officers) of a publicly traded company buy or sell the company's securities. This provides transparency to the market.

Stakeholder Impact

• The acquisition of stock options by a director could signal confidence to shareholders.

Key Dates